{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:25:14Z","timestamp":1793816714660,"version":"4.6.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.antiviral.2020.104995","type":"journal-article","created":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T10:26:09Z","timestamp":1607855169000},"page":"104995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis"],"prefix":"10.1016","volume":"185","author":[{"given":"Aigerim","family":"Abdrakhman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1159-9819","authenticated-orcid":false,"given":"Aiymkul","family":"Ashimkhanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1633-9757","authenticated-orcid":false,"given":"Wassim Y.","family":"Almawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104995_bib1","first-page":"CD006002","article-title":"Interferon alpha for chronic hepatitis","volume":"2011","author":"Abbas","year":"2011","journal-title":"D. Cochrane Database Syst. Rev."},{"key":"10.1016\/j.antiviral.2020.104995_bib2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.4254\/wjh.v8.i14.625","article-title":"Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: a randomized trial","volume":"8","author":"Abbas","year":"2016","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104995_bib3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3851\/IMP2728","article-title":"Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience","volume":"19","author":"Abbas","year":"2014","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2020.104995_bib4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3851\/IMP2943","article-title":"Interferon lambda-3 polymorphism and response to pegylated interferon in patients with hepatitis","volume":"20","author":"Abbas","year":"2015","journal-title":"D. Antivir. Ther."},{"key":"10.1016\/j.antiviral.2020.104995_bib5","first-page":"967","article-title":"Standard and pegylated interferon therapy of HDV infection: a systematic review and meta-analysis","volume":"17","author":"Alavian","year":"2012","journal-title":"J. Res. Med. Sci."},{"key":"10.1016\/j.antiviral.2020.104995_bib6","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.24366","article-title":"Pegylated interferon \u03b1 therapy in chronic delta hepatitis: a one-center experience","volume":"15","author":"Bahcecioglu","year":"2015","journal-title":"Hepat. Mon."},{"key":"10.1016\/j.antiviral.2020.104995_bib7","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/jmv.25438","article-title":"Antiviral treatment with pegylated interferon and clinical outcomes in a cohort of immigrants patients affected by hepatitis delta: a retrospective analysis","volume":"91","author":"Boglione","year":"2019","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.antiviral.2020.104995_bib8","series-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2011"},{"key":"10.1016\/j.antiviral.2020.104995_bib9","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/hep.21325","article-title":"Efficacy of peginterferon alpha\u20102b in chronic hepatitis delta: relevance of quantitative RT\u2010PCR for follow\u2010up","volume":"44","author":"Castelnau","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104995_bib10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jhep.2019.11.003","article-title":"EASL-AASLD HBV treatment endpoints conference faculty., 2020. Guidance for design and endpoints of clinical trials in chronic hepatitis B\u2014report from the 2019 EASL\u2010AASLD HBV treatment endpoints conference","volume":"72","author":"Cornberg","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104995_bib11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.24875\/AIDSRev.19000080","article-title":"Beyond pegylated interferon-alpha: new treatments for hepatitis delta","volume":"21","author":"Deterding","year":"2019","journal-title":"AIDS Rev."},{"key":"10.1016\/j.antiviral.2020.104995_bib12","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1478-3231.2006.01279.x","article-title":"Treatment of chronic hepatitis delta with pegylated interferon\u2010\u03b12b","volume":"26","author":"Erhardt","year":"2006","journal-title":"Liver Int."},{"key":"10.1016\/j.antiviral.2020.104995_bib13","first-page":"377","article-title":"Weight-based dosing regimen of peg-interferon \u03b1-2b for chronic hepatitis delta: a multicenter Romanian trial","volume":"20","author":"Gheorghe","year":"2011","journal-title":"J Gastrointestin. Liver Dis."},{"key":"10.1016\/j.antiviral.2020.104995_bib14","doi-asserted-by":"crossref","first-page":"731","DOI":"10.5812\/kowsar.1735143X.2462","article-title":"Treatment of chronic delta hepatitis: a nine-year retrospective analysis","volume":"11","author":"Gulsun","year":"2011","journal-title":"Hepat. Mon."},{"key":"10.1016\/j.antiviral.2020.104995_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/apt.12788","article-title":"Long\u2010term therapy of chronic delta hepatitis with peginterferon alfa","volume":"40","author":"Heller","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.antiviral.2020.104995_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104995_bib17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3851\/IMP2381","article-title":"Efficacy of pegylated interferon-\u03b1 treatment for 24 months in chronic delta hepatitis and predictors of response","volume":"18","author":"Karaca","year":"2013","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2020.104995_bib18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.cld.2019.04.005","article-title":"HBV\/HDV coinfection: a challenge for therapeutics","volume":"23","author":"Koh","year":"2019","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.antiviral.2020.104995_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jare.2019.03.009","article-title":"A review on hepatitis D: from virology to new therapies","volume":"17","author":"Mentha","year":"2019","journal-title":"J. Adv. Res."},{"issue":"3","key":"10.1016\/j.antiviral.2020.104995_bib20","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.21296","article-title":"Pegylated interferon alpha\u20102b as monotherapy or in combination with ribavirin in chronic hepatitis delta","volume":"44","author":"Niro","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2020.104995_bib21","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jhep.2016.05.043","article-title":"Aiming for cure in HBV and HDV infection","volume":"65","author":"Petersen","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2020.104995_bib22","doi-asserted-by":"crossref","DOI":"10.1590\/0037-8682-0289-2018","article-title":"Hepatitis delta prevalence in south America: a systematic review and meta-analysis","volume":"52","author":"Scarponi","year":"2019","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"10.1016\/j.antiviral.2020.104995_bib23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/cld.254","article-title":"Treatment of hepatitis delta","volume":"2","author":"Wedemeyer","year":"2013","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.antiviral.2020.104995_bib24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(18)30663-7","article-title":"Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial","volume":"19","author":"Wedemeyer","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104995_bib25","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104995_bib26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.coviro.2016.10.002","article-title":"Antiviral therapy of hepatitis delta virus infection \u2014 progress and challenges towards cure","volume":"20","author":"Wranke","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2020.104995_bib27","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/hep.28876","article-title":"Antiviral treatment and liver\u2010related complications in hepatitis delta","volume":"65","author":"Wranke","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.antiviral.2020.104995_bib28","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1365-2893.2007.00936.x","article-title":"Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon","volume":"15","author":"Yurdayd\u0131n","year":"2008","journal-title":"J. Viral Hepat."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220304095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220304095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:33:40Z","timestamp":1759062820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354220304095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":28,"alternative-id":["S0166354220304095"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104995","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104995","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104995"}}